1-Acetyl-4-(3-phenyl-2-propenyl)piperazin | 21801-24-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-Acetyl-4-(3-phenyl-2-propenyl)piperazin
• 英文别名: 1-Acetyl-4-trans-cinnamyl-piperazin；1-acetyl-4-(3-phenyl-allyl)-piperazine；1-[4-[(E)-3-phenylprop-2-enyl]piperazin-1-yl]ethanone
• CAS: 21801-24-1
• 化学式: C₁₅H₂₀N₂O
• 分子量: 244.337
• InChiKey: IXFLEYAVUQUPCA-VMPITWQZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  23.6
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  肉桂基哌嗪 、 乙酸酐 、 吡啶 生成 1-Acetyl-4-(3-phenyl-2-propenyl)piperazin
  参考文献：
  名称：

  MAURER, HANS;PFLIEGER, KARL, FRESENIUS Z. ANAL. CHEM., 331,(1988) N 7, 744-756

  摘要：

  DOI：

文献信息

• Novel Tetracyclic Tetrahydrofuran Derivatives Containing Cyclic Amine Side Chain
  申请人：Cid-Nunez Jose Maria

  公开号：US20080262076A1

  公开（公告）日：2008-10-23

  This invention concerns novel substituted tetracyclic tetrahydrofuran derivatives containing a cyclic amine side chain with binding affinities towards dopamine receptors, in particular dopamine D 2 receptors, towards serotonin receptors, in particular 5-HT 2A and 5-HT 2C receptors, and pharmaceutical compositions comprising the compounds according to the invention, the use thereof as a medicine, in particular for the prevention and/or treatment of a range of psychiatric and neurological disorders, in particular certain psychotic, cardiovascular and gastrokinetic disorders and processes for their production. The compounds according to the invention can be represented by general Formula (I) and comprises also a pharmaceutically acceptable acid or base addition salt thereof, an N-oxide form thereof or a quaternary ammonium salt thereof, wherein all substituents are defined as in Claim 1.

  本发明涉及一种新型取代四环四氢呋喃衍生物，其含有一个环状胺侧链，具有结合多巴胺受体的亲和力，特别是多巴胺D2受体，对5-HT2A和5-HT2C受体的亲和力，以及包含根据本发明的化合物的制药组合物，其用作药物，特别是用于预防和/或治疗一系列精神和神经疾病，特别是某些精神病、心血管和胃动力紊乱，并提供其生产过程。根据本发明的化合物可以用一般式（I）表示，并包括其药学上可接受的酸或碱盐、N-氧化物形式或季铵盐，其中所有取代基在权利要求书1中定义。
• Novel dihydropyridine derivatives and process for preparing the same
  申请人：OTSUKA PHARMACEUTICAL CO., LTD.

  公开号：EP0145434A2

  公开（公告）日：1985-06-19

  Dihydropyridine derivatives and salts thereof represented by the general formula, which possess excellent calcium antagonist effect, hypoten- sive effect, platelets aggregation inhibitory effect, phosphodiesterase inhibitory effect, calmodulin inhibitory effect and peroxidized lipid lowering effect, and thus dihydropyridine derivatives and salts thereof are useful as a coronary blood flow improving agent such as coronary vasodilator, hypotensive agent, prophylaxis and treating agents for thrombosis, phosphodiesterase inhibitory agent, peroxidized lipid metabolism lowering agent, anti-inflammatory agent and others.

  通式代表的二氢吡啶衍生物及其盐、 具有良好的钙拮抗剂作用、降血压作用、血小板聚集抑制作用、磷酸二酯酶抑制作用、钙调素抑制作用和过氧化脂质降低作用、因此，二氢吡啶衍生物及其盐类可用作冠状动脉血流改善剂，如冠状动脉血管扩张剂、降血压剂、血栓预防和治疗剂、磷酸二酯酶抑制剂、过氧化脂质代谢降低剂、消炎剂等。
• TXNIP-TRX complex inhibitors and methods of using the same
  申请人：CITY OF HOPE

  公开号：US11324731B2

  公开（公告）日：2022-05-10

  Disclosed herein, inter alia, are compounds and methods for inhibiting the thioredoxin-thioredoxin-interacting-protein (TXNIP-TRX) complex.

  本文特别公开了抑制硫氧还蛋白-硫氧还蛋白-相互作用蛋白（TXNIP-TRX）复合物的化合物和方法。
• TXNIP-TRX COMPLEX INHIBITORS AND METHODS OF USING THE SAME
  申请人：CITY OF HOPE

  公开号：US20200085800A1

  公开（公告）日：2020-03-19

  Disclosed herein, inter alia, are compounds and methods for inhibiting the thioredoxin-thioredoxin-interacting-protein (TXNIP-TRX) complex.
• US5034395A
  申请人：——

  公开号：US5034395A

  公开（公告）日：1991-07-23